PROCAPS GROUP SA (PROC)
$4.27
+0.02
(+0.47%)▲
Insights on PROCAPS GROUP SA
Decreasing Revenue
Revenue is down for the last 4 quarters, 112.42M → 81.19M (in $), with an average decrease of 9.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 22.58M → -4.25M (in $), with an average decrease of 59.4% per quarter
Vs NBIX
In the last 1 year, Procaps Group S.A has experienced a drawdown of -46.7%, however Neurocrine Biosciences, Inc. resisted the overall trend and outperformed by 45.0%
Performance
- $4.15$4.29$4.27
2.81%
Downside
Day's Volatility :3.27%
Upside
0.47%
- $3.68$9.50$4.27
13.82%
Downside
52 Weeks Volatility :61.26%
Upside
55.05%
Returns
| Period | PROCAPS GROUP SA | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 1.67% | 0.3% | -6.7% |
6 Months | -34.21% | -6.1% | -3.7% |
1 Year | -49.82% | -4.8% | -6.3% |
3 Years | -58.14% | 23.8% | 26.9% |
Highlights
Market Capitalization | 479.5M |
Book Value | - $0.01 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 0.43 |
PE Ratio | 9.88 |
Wall Street Target Price | 7.0 |
Profit Margin | 10.38% |
Operating Margin TTM | 13.43% |
Return On Assets TTM | 7.46% |
Return On Equity TTM | 46.32% |
Revenue TTM | 409.9M |
Revenue Per Share TTM | 4.05 |
Quarterly Revenue Growth YOY | -19.8% |
Gross Profit TTM | 191.3M |
EBITDA | 62.9M |
Diluted Eps TTM | 0.43 |
Quarterly Earnings Growth YOY | -0.63 |
EPS Estimate Current Year | 0.33 |
EPS Estimate Next Year | 0.43 |
EPS Estimate Current Quarter | -0.04 |
EPS Estimate Next Quarter | 0.06 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 63.93%
Company Financials
| FY19 | Y/Y Change | |
|---|---|---|
Revenue | 324.8M | - |
Net Income | -17.0M | - |
Net Profit Margin | -5.24% | - |
| FY20 | Y/Y Change | |
|---|---|---|
Revenue | 331.5M | ↑ 2.06% |
Net Income | -10.4M | ↓ 38.58% |
Net Profit Margin | -3.15% | ↑ 2.09% |
| FY21 | Y/Y Change | |
|---|---|---|
Revenue | 409.7M | ↑ 23.61% |
Net Income | -100.9M | ↑ 865.47% |
Net Profit Margin | -24.62% | ↓ 21.47% |
| FY22 | Y/Y Change | |
|---|---|---|
Revenue | 409.9M | ↑ 0.04% |
Net Income | 42.5M | ↓ 142.18% |
Net Profit Margin | 10.38% | ↑ 35.0% |
| Q4 FY21 | Q/Q Change | |
|---|---|---|
Revenue | 126.5M | ↑ 18.45% |
Net Income | -46.3M | ↑ 25.37% |
Net Profit Margin | -36.58% | ↓ 2.02% |
| Q1 FY22 | Q/Q Change | |
|---|---|---|
Revenue | 85.6M | ↓ 32.33% |
Net Income | 16.4M | ↓ 135.53% |
Net Profit Margin | 19.21% | ↑ 55.79% |
| Q2 FY22 | Q/Q Change | |
|---|---|---|
Revenue | 112.4M | ↑ 31.29% |
Net Income | -6.9M | ↓ 142.07% |
Net Profit Margin | -6.15% | ↓ 25.36% |
| Q3 FY22 | Q/Q Change | |
|---|---|---|
Revenue | 110.4M | ↓ 1.79% |
Net Income | 22.6M | ↓ 426.35% |
Net Profit Margin | 20.45% | ↑ 26.6% |
| Q4 FY22 | Q/Q Change | |
|---|---|---|
Revenue | 81.2M | ↓ 26.45% |
Net Income | -4.3M | ↓ 118.83% |
Net Profit Margin | -5.24% | ↓ 25.69% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 81.2M | ↑ 0.0% |
Net Income | -4.3M | ↑ 0.0% |
Net Profit Margin | -5.24% | ↑ 0.0% |
| FY19 | Y/Y Change | |
|---|---|---|
Total Assets | 337.7M | - |
Total Liabilities | 581.7M | - |
| FY20 | Y/Y Change | |
|---|---|---|
Total Assets | 359.5M | ↑ 6.46% |
Total Liabilities | 614.2M | ↑ 5.59% |
| FY21 | Y/Y Change | |
|---|---|---|
Total Assets | 462.1M | ↑ 28.54% |
Total Liabilities | 500.5M | ↓ 18.52% |
| FY22 | Y/Y Change | |
|---|---|---|
Total Assets | 460.2M | ↓ 0.42% |
Total Liabilities | 462.1M | ↓ 7.67% |
| Q4 FY21 | Q/Q Change | |
|---|---|---|
Total Assets | 462.1M | ↓ 0.56% |
Total Liabilities | 500.5M | ↑ 16.81% |
| Q1 FY22 | Q/Q Change | |
|---|---|---|
Total Assets | 483.3M | ↑ 4.57% |
Total Liabilities | 502.9M | ↑ 0.49% |
| Q2 FY22 | Q/Q Change | |
|---|---|---|
Total Assets | 470.2M | ↓ 2.71% |
Total Liabilities | 499.8M | ↓ 0.63% |
| Q3 FY22 | Q/Q Change | |
|---|---|---|
Total Assets | 471.2M | ↑ 0.21% |
Total Liabilities | 481.7M | ↓ 3.62% |
| Q4 FY22 | Q/Q Change | |
|---|---|---|
Total Assets | 84.4M | ↓ 82.08% |
Total Liabilities | 145.4M | ↓ 69.81% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 84.4M | ↑ 0.0% |
Total Liabilities | 145.4M | ↑ 0.0% |
| FY19 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 68.3M | - |
Investing Cash Flow | -12.1M | - |
Financing Cash Flow | -46.9M | - |
| FY20 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | 70.9M | ↑ 3.86% |
Investing Cash Flow | -17.1M | ↑ 41.61% |
Financing Cash Flow | -40.5M | ↓ 13.72% |
| Q4 FY21 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 6.3M | ↑ 0.0% |
Investing Cash Flow | -4.2M | ↑ 0.0% |
Financing Cash Flow | -10.2M | ↑ 0.0% |
| Q1 FY22 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 6.3M | ↑ 0.0% |
Investing Cash Flow | -4.2M | ↑ 0.0% |
Financing Cash Flow | -10.2M | ↑ 0.0% |
| Q2 FY22 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 10.0M | ↑ 57.25% |
Investing Cash Flow | -8.9M | ↑ 114.28% |
Financing Cash Flow | -26.0M | ↑ 156.18% |
| Q3 FY22 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | 5.8M | ↓ 42.21% |
Investing Cash Flow | -7.5M | ↓ 16.3% |
Financing Cash Flow | -5.4M | ↓ 79.41% |
Technicals Summary
Sell
Neutral
Buy
PROCAPS GROUP SA is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 PROCAPS GROUP SA | -7.58% | -34.21% | -49.82% | -58.14% | -58.14% |
 Neurocrine Biosciences Inc. | -12.02% | -24.82% | -2.11% | -26.64% | -2.82% |
 Zoetis Inc. | -8.25% | 11.42% | -3.62% | 18.19% | 98.12% |
 Viatris Inc. | -2.72% | -18.56% | -25.79% | -44.28% | -44.28% |
 Catalent, Inc. | -25.94% | -21.32% | -63.98% | -52.24% | -4.13% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
PROCAPS GROUP SA | 9.88 | 9.88 | NA | 0.33 | 0.46 | 0.07 | 0.0 | -0.01 |
Neurocrine Biosciences Inc. | 148.68 | 148.68 | 1.87 | 1.93 | 0.04 | 0.08 | 0.0 | 17.28 |
Zoetis Inc. | 37.47 | 37.47 | 3.53 | 5.4 | 0.45 | 0.13 | 0.01 | 9.72 |
Viatris Inc. | 5.82 | 5.82 | NA | 2.95 | 0.09 | 0.03 | 0.05 | 17.45 |
Catalent, Inc. | 16.21 | 16.21 | 1.18 | 1.37 | 0.09 | 0.04 | 0.0 | 27.29 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
PROCAPS GROUP SA | Buy | $479.5M | -58.14% | 9.88 | 10.38% |
Neurocrine Biosciences Inc. | Buy | $9.0B | -2.82% | 148.68 | 4.0% |
Zoetis Inc. | Buy | $76.4B | 98.12% | 37.47 | 25.59% |
Viatris Inc. | Hold | $10.9B | -44.28% | 5.82 | 12.05% |
Catalent, Inc. | Buy | $6.7B | -4.13% | 16.21 | 8.62% |
Institutional Holdings
Compass Group LLC
0.48%Millennium Management LLC
0.06%Geode Capital Management, LLC
0.02%State Street Corporation
0.01%
Company Information
Procaps is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in Latin America and, as of December 31, 2020, had more than 4,700 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.
Organization | PROCAPS GROUP SA |
Employees | 5500 |
CEO | Mr. Ruben Minski |
Industry | Healthcare |
Discover More
Presto Automation Inc
$3.59
+63.93%
D-MARKET ELECTRONIC SERVICES
$1.04
+4.0%
Mexico MSCI Capped ETF iShares
$61.22
+2.03%
Global X S&P Catholic Values Developed ex-US ETF
$27.84
+0.0%
IndexIQ ETF Trust - IQ Chaikin U.S. Small Cap ETF
$30.75
+0.5%
DFA Dimensional Internatl High Profitability ETF
$24.08
+1.09%
Precigen Inc
$1.22
+1.67%
EXSCIENTIA PLC
$7.96
+1.14%
ISHARES GEN-IMMUNOLOGY HLTH
$24.03
+0.92%